Sugi Predict

Sugi Predict / Compounds / SCHEMBL1723265

SCHEMBL1723265

SCHEMBL1723265

O=C1c2ccccc2C(=O)N1C1C=C(c2ccncc2[N+](=O)[O-])CCC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.43
▸ GRM5 P41594 1/20 0.43
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ DDB1 Q16531 2/20 0.38
▸ CRBN Q96SW2 2/20 0.38
▸ ALDH1A1 P00352 3/20 0.36
▸ MAPT P10636 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ HTT P42858 3/20 0.33
▸ POLB P06746 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ CCR6 P51684 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1723326 0.84 MEN1 (0.39) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL15913993 0.83 DDB1 (0.37) CYP1A2GRM5MEN1KMT2ADDB1
SCHEMBL13833230 0.83 DDB1 (0.37) CYP1A2GRM5MEN1KMT2ADDB1
SCHEMBL15913994 0.83 DDB1 (0.37) CYP1A2GRM5MEN1KMT2ADDB1
SCHEMBL1723150 0.82 CYP1A2 (0.47) CYP1A2GRM5DDB1CRBNALDH1A1
SCHEMBL1711337 0.81 KDM4E (0.34) CYP1A2MEN1KMT2ADDB1CRBN
SCHEMBL1711664 0.77 KMT2A (0.44) MEN1KMT2AALDH1A1MAPTKDM4E
SCHEMBL13736491 0.76 CYP1A2 (0.44) CYP1A2GRM5DDB1CRBNALDH1A1
SCHEMBL13833544 0.76 CYP1A2 (0.44) CYP1A2GRM5DDB1CRBNALDH1A1
SCHEMBL13736789 0.76 CYP1A2 (0.42) CYP1A2GRM5DDB1CRBNALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2943485-B1 BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE HOLDINGS CORP (US) 2017-09-20 — — EP disclosed
US-9676750-B2 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2017-06-13 — — US disclosed
US-9676750-B2 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2017-06-13 — — US disclosed
US-20160137626-A1 BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION (US) 2016-05-19 — — US disclosed
US-20160137626-A1 BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS INCYTE CORPORATION (US) 2016-05-19 — — US disclosed
US-9278950-B2 Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2016-03-08 — — US disclosed
US-9278950-B2 Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors INCYTE CORPORATION (US) 2016-03-08 — — US disclosed
US-20150336960-A1 ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS NOVARTIS AG (CH) 2015-11-26 — — US disclosed
US-20150336960-A1 ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS NOVARTIS AG (CH) 2015-11-26 — — US disclosed
US-20150336960-A1 ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS NOVARTIS AG (CH) 2015-11-26 — — US disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 — — US disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 — — US disclosed
US-20100216839-A1 Pim kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-08-26 — — US disclosed
WO-2010026124-A1 PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-11 — — WO disclosed
WO-2010026124-A1 PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-11 — — WO disclosed
US-20100056576-A1 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-03-04 — — US disclosed
US-20100056576-A1 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-03-04 — — US disclosed
US-20100056576-A1 Kinase inhibitors and methods of their use NOVARTIS AG (CH) 2010-03-04 — — US disclosed
WO-2009109576-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2009-09-11 — — WO disclosed
WO-2009109576-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2009-09-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137626-A1 BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 CYP1A2 2984/4885GRM5 3965/4885MEN1 4226/4885
US-20100056576-A1 Kinase inhibitors and methods of their use PIM1, PIM2, PIM3 CYP1A2 4109/4885GRM5 3006/4885MEN1 2942/4885
US-20100216839-A1 Pim kinase inhibitors and methods of their use PIM1, PIM2, PIM3 CYP1A2 1147/4885GRM5 4471/4885MEN1 3664/4885
US-20150336960-A1 ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS PIM1, PIM2, PIM3 CYP1A2 338/4885GRM5 1233/4885MEN1 4161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.